[Prospective perimenopausal estrogen-progestin substitution therapies for the prevention of osteoporosis].
Dören
M
M
Westfälische Wilhelms-Universität Münster.
Montag
M
M
Schneider
H P
HP
D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004964:Estriol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D011446:Prospective Studies
D004958:Estradiol; D000077563:Norethindrone Acetate; D017258:Medroxyprogesterone Acetate; D004964:Estriol; D008525:Medroxyprogesterone; D009640:Norethindrone
Prospektive perimenopausale Ostrogen-Gestagen-Substitutionstherapien zur Osteoporoseprävention.